INS and obesity disorder: GLP-1 receptor agonists (GLP-1 RAs) are an important class of non-insulin injectable glucose-lowering therapies that deliver clinically meaningful HA1C reductions with low intrinsic risk of hypoglycemia and consistent weight loss, benefits that are particularly pertinent for people with T2D and overweight/obesity in primary care settings [32, 33].